Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $3-Report released on 9th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained a Neutral rating on Humacyte (NASDAQ:HUMA) but reduced the price target from $3.5 to $3, as reported on November 9, 2023.
November 10, 2023 | 10:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler maintains a Neutral stance on Humacyte but lowers the price target from $3.5 to $3.
The reduction in price target by Piper Sandler could lead to a negative perception among investors, potentially causing a short-term decline in HUMA's stock price. The Neutral rating suggests no significant change in the company's outlook, but the lower price target indicates a reduced valuation expectation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100